-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 1, the Fujian Provincial Medical Insurance Bureau issued a notice announcing the results of the proposed selection of the third batch of drugs in Fujian Province in 2022, with a total of 43 varieties, including 3 biological agents
.
According to data from Intranet, the total sales scale of the above 43 varieties in public hospitals in Fujian Province in 2021 exceeded 400 million yuan, of which the sales of leuprolide injection, gadolinopentethate meglumine injection, ondansetron oral regular release agent and other varieties exceeded 10 million yuan
.
.
According to data from Intranet, the total sales scale of the above 43 varieties in public hospitals in Fujian Province in 2021 exceeded 400 million yuan, of which the sales of leuprolide injection, gadolinopentethate meglumine injection, ondansetron oral regular release agent and other varieties exceeded 10 million yuan
.
According to the Minenet combing, the centralized procurement of drugs in Fujian Province (the third batch) covers all public medical institutions in Fujian Province, and medical institutions designated by medical insurance can participate
voluntarily.
Within 12 months of the implementation of the selection results, each public medical institution will give priority to the use of the selected varieties, and the amount used shall not be less than 60%
of the total use of the same group in principle.
voluntarily.
Within 12 months of the implementation of the selection results, each public medical institution will give priority to the use of the selected varieties, and the amount used shall not be less than 60%
of the total use of the same group in principle.
The collection was divided
into two groups, A and B.
If Group A is selected for 100% of the procurement quantity of Group B, 50% of Group A will be allocated to Group B; If 50% of the purchase volume of Group B is selected, 25% of Group A will be allocated to Group
B.
In addition, when the selected price in group B is higher than group A, price correction will be carried out, and if it is unwilling, the group will be processed
as a flow label.
into two groups, A and B.
If Group A is selected for 100% of the procurement quantity of Group B, 50% of Group A will be allocated to Group B; If 50% of the purchase volume of Group B is selected, 25% of Group A will be allocated to Group
B.
In addition, when the selected price in group B is higher than group A, price correction will be carried out, and if it is unwilling, the group will be processed
as a flow label.
Compared with the previous list of reported (a total of 50 varieties), 7 varieties, including idebenone, oxcarbazepine, live bacteria licheniformis, clohexin (compound cefaclor), propoxau, ziprasidone, silybin meglumine, etc.
, did not appear in the list of proposed selection results, and the final processing results are expected to be officially announced
after the end of the publicity period.
, did not appear in the list of proposed selection results, and the final processing results are expected to be officially announced
after the end of the publicity period.
Varieties with sales of more than 10 million yuan in the centralized procurement of drugs in Fujian Province (10,000 yuan)
Source: Terminal competition pattern of public hospitals in key provinces and cities on the intranet
The list of candidates includes 43 varieties, and the total sales scale of public hospitals in Fujian Province in 2021 exceeds 400 million yuan
.
Among them, leuprolide injection, recombinant human coagulation factor VIII injection, tacrolimus oral regular release, ondansetron oral regular release, compound sodium acetate Ringer injection, gadolinopentate meglumine injection, hydroxyethyl starch 130/0.
4 sodium chloride injection and other varieties of sales exceeded 10 million yuan
.
.
Among them, leuprolide injection, recombinant human coagulation factor VIII injection, tacrolimus oral regular release, ondansetron oral regular release, compound sodium acetate Ringer injection, gadolinopentate meglumine injection, hydroxyethyl starch 130/0.
4 sodium chloride injection and other varieties of sales exceeded 10 million yuan
.
Sales of leuprolide injection, triptorelin injection and recombinant human coagulation factor VIII injection in public hospitals in Fujian Province (10,000 yuan)
Source: Terminal competition pattern of public hospitals in key provinces and cities on the intranet
It is worth mentioning that leuprolide injection and triptorelin injection are both analogues of gonadotropin-releasing hormone, which are mainly used for endometriosis, uterine fibroids, central precocious puberty and other diseases
.
In recent years, the terminal sales growth rate of both in public hospitals in Fujian Province has reached double digits, with sales exceeding 100 million yuan and 20 million yuan in 2021, respectively, a year-on-year increase of 16.
97% and 64.
92%.
.
In recent years, the terminal sales growth rate of both in public hospitals in Fujian Province has reached double digits, with sales exceeding 100 million yuan and 20 million yuan in 2021, respectively, a year-on-year increase of 16.
97% and 64.
92%.
The sales performance of recombinant human coagulation factor VIII injection, one of the three biological agents, is also gratifying, and the terminal sales revenue of public hospitals in Fujian Province exceeded 40 million yuan in 2021, a year-on-year increase of 15.
58%.
From the perspective of the competition pattern of manufacturers, Takeda Pharmaceutical's market share accounts for more than 50%.
58%.
From the perspective of the competition pattern of manufacturers, Takeda Pharmaceutical's market share accounts for more than 50%.
The results of the 2022 Fujian Province drug collective procurement (third batch) are to be selected
Data source: Intranet database, official website of the Medical Insurance Bureau
Note: The chemical drug terminal competition pattern database of public hospitals in key provinces and cities is based on the chemical drug procurement data of nearly 700 sample provinces and cities in 20+ provinces and cities, and continuously monitors the sample provincial and municipal sample hospital database
of all chemical drug categories.
of all chemical drug categories.
